The following technologies have recently been added to the Isis Innovation portfolio. For more information or to arrange a conversation with one of our project managers please e-mail: [email protected]
Inhibitors in Allergy and Inflammation
Researchers
at the University of Oxford have identified an inhibitor with potential
therapeutic use for the treatment of allergy and inflammatory disorders.
Prevention of Auto-Reactivity with Inhibitory Antibody Superagonists
A new method to inhibit auto-reactivity using antibody superagonists
that specifically target inhibitory cell surface receptors reliant on
extrinsic tyrosine kinases.
A New Treatment for Neurodegenerative Disease
A novel mechanism to protect neurons from the cell death underlying Parkinson’s disease.
A Neurotrophic Compound in Treatment of Depression
Research at Oxford University’s experimental psychology department has
demonstrated a potential new drug treatment for depression.
MRI Protection for Occupationally-Exposed Workers
An innovative MRI screen technology meets the new European limits for
protecting exposed workers from time-varying electromagnetic fields
during MRI scanning.
The Oxford FMRIB (Functional Magnetic Resonance Imaging of the Brain) group is dedicated to the continual improvement and understanding of functional MRI, and has recently issued version 3.3 of its well proven software library (FSL).
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
